Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina (ANISSA)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: August 31, 2005
Last updated: April 17, 2007
Last verified: April 2007

The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia

Condition Intervention Phase
Myocardial Ischemia
Drug: Amlodipine
Drug: iso- 5 - mononitrate
Procedure: Blood tests
Procedure: Exercise Stress Test
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Study Comparing Amlodipine vs Long-Acting Nitrates in Patients With Chronic Stable Angina.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Evaluate the time to 1mm ST depression

Secondary Outcome Measures:
  • The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety

Estimated Enrollment: 200
Study Start Date: April 2001
Estimated Study Completion Date: January 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients > =18 years of age with diagnosed clinically stable angina pectoris

Exclusion Criteria:

  • Patients with congestive heart failure, clinically significant cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143195

Pfizer Investigational Site
Athens, Attika, Greece, 11527
Pfizer Investigational Site
Athens, Greece, 123 51
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Holargos/Athens, Greece, 11525
Pfizer Investigational Site
Loannina, Greece, 45500
Pfizer Investigational Site
N. Ionia, Greece, 143 88
Pfizer Investigational Site
Patra, Greece, 26335
Pfizer Investigational Site
Rio, Patra, Greece, 26499
Pfizer Investigational Site
Thessaloniki, Greece, 54639
Pfizer Investigational Site
Thessaloniki, Greece, 546 36
Pfizer Investigational Site
Voula/Athens, Greece
Pfizer Investigational Site
Zakynthos, Greece, 29100
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided Identifier: NCT00143195     History of Changes
Other Study ID Numbers: A0531076
Study First Received: August 31, 2005
Last Updated: April 17, 2007
Health Authority: Greece: National Organization of Medicines

Additional relevant MeSH terms:
Angina, Stable
Coronary Artery Disease
Myocardial Ischemia
Angina Pectoris
Arterial Occlusive Diseases
Cardiovascular Diseases
Chest Pain
Coronary Disease
Heart Diseases
Signs and Symptoms
Vascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents processed this record on November 20, 2014